Listed by the USPTO as ZHU, JIANJIAN
Tech Center 1600 • Art Units: 1631 1632 1635 1699
This examiner grants 58% of resolved cases
ZHU, JIANJIAN is assigned to Tech Center 1600 and Art Unit 1631. The record contains 86 resolved cases and an allowance rate of 58.1%. The median time to allowance is 1353 days, so applicants should plan for extended prosecution and preserve flexibility around related filings.
The interview lift is 82.5%, the strongest stated association in this profile. A practitioner may therefore give substantial attention to interview preparation, including a precise explanation of claim scope and the proposed response to each outstanding issue. The represented organizations are Fate Therapeutics Inc., Lung Biotechnology Pbc, and The Board of Trustees of the Leland Stanford Junior University. The listed firms are Foley & Lardner LLP, WOLF GREENFIELD & SACKS, P.C., and Arnold & Porter Kaye Scholer LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17549028 | PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE | Non-Final OA | The Regents of the University of Michigan |
| 17436131 | TARGETED DELIVERY OF IMMUNE-MODULATING VHH AND VHH-FUSION PROTEIN | Non-Final OA | Massachusetts Institute of Technology |
| 18026474 | CELL SUPPORT AND METHOD OF PRODUCING SAME, CELL CULTURE METHOD AND CELL STRUCTURE | Final Rejection | Konica Minolta, Inc. |
| 18978181 | FOAMY VIRUSES AND METHODS OF USE | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17495597 | MULTICELL CONJUGATES FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | Wisconsin Alumni Research Foundation |
| 17669904 | DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY | Non-Final OA | The General Hospital Corporation |
| 18696014 | TREATMENT OF POLYCYTHEMIA VERA VIA CRISPR/AAV6 GENOME EDITING | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17168988 | ARRDC1-MEDIATED MICROVESICLES (ARMMS) AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18941862 | BIOACTIVE AND ANTIOXIDANT SUPRAMOLECULAR POLYMER HYDROGELS FOR NEURAL CELL CULTURE | Non-Final OA | Northwestern University |
| 18929526 | COST EFFECTIVE CULTURE MEDIA AND PROTOCOL FOR HUMAN INDUCED PLURIPOTENT STEM CELLS | Non-Final OA | Northwestern University |
| 16960445 | 3D in vitro Models of Lung Tissue | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18868301 | MANIPULATING NEPHRON DIFFERENTIATION RATE IN INDUCED HUMAN PLURIPOTENT STEM CELL ORGANOIDS AND TISSUES BY ENGINEERING MECHANICS OF THE MICROENVIRONMENT | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18504261 | GENE THERAPY FOR OCULAR DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 19102450 | CARRIER PEPTIDE FRAGMENT AND USE THEREOF | Non-Final OA | TOAGOSEI CO., LTD. |
| 18981938 | PHYSIOLOGICAL BIOMIMETIC CULTURE SYSTEM FOR HEART SLICES | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 17511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | Final Rejection | Capricor, Inc. |
| 17192736 | PLATFORM ONCOLYTIC VECTOR FOR SYSTEMIC DELIVERY | Non-Final OA | KaliVir Immunotherapeutics LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.1% of resolved applications examined by Jianjian Zhu were allowed (86 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +82.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jianjian Zhu took 1,353 days on average from filing to allowance.
Jianjian Zhu examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
